AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Pharvaris N.V.
Video analysis: PHVS
All videosNo video analysis for this stock yet. Request one from our team.
News: PHVS
Pharvaris: 'Strong Buy' Based On Deucrictibant PDUFA And Prophylaxis Trial Win
Pharvaris N.V. maintains a 'Strong Buy' rating following pivotal phase 3 wins for both on-demand and prophylactic HAE therapies. PHVS achieved rapid symptom relief in RAPIDe-3 [median 1.28 hours, p
Pharvaris N.V. (PHVS) Discusses Topline Results of Chapter-3 Phase III Study on Deucrictibant for Prophylactic Treatment of Hereditary Angioedema Transcript
Pharvaris N.V. (PHVS) Discusses Topline Results of Chapter-3 Phase III Study on Deucrictibant for Prophylactic Treatment of Hereditary Angioedema Transcript
Pharvaris' genetic disorder drug meets main goal in late-stage trial
Pharvaris said on Tuesday its experimental oral drug helped prevent swelling attacks in patients with hereditary angioedema, meeting the main goal of a late-stage trial.
Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks
ZUG, Switzerland, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema (AE-BK), such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced statistically significant and clinically meaningful topline results of the CHAPTER-3 pivotal Phase 3 study evaluating deucrictibant extended-release (XR) tablet for the prevention of HAE attacks. The primary endpoint and all secondary efficacy endpoints were met with statistical significance. Data from the CHAPTER-3 study will serve as the basis for marketing authorization applications, which are planned to be submitted starting in the first half of 2027.
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It
Drug pricing is back on the front page, and healthcare investors have barely flinched. The White House's latest round of most-favored-nation pricing agreements brought nine more manufacturers into the fold, pushing the total to 26 companies covering 89% of the branded drug market.
Pharvaris Presents Translational, Nonclinical, and Clinical Data at Bradykinin Symposium 2026
ZUG, Switzerland, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema, such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), summarized the oral and poster presentations from the Bradykinin Symposium 2026, which will take place from September 3-4, 2026, in Berlin, Germany.
BlackRock Inc. Makes New Investment in Pharvaris N.V. $PHVS
BlackRock Inc. purchased a new stake in shares of Pharvaris N.V. (NASDAQ: PHVS) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 771,454 shares of the company's stock, valued at approximately $26,677,000. BlackRock Inc. owned about 1.18% of Pharvaris at the end of
5AM Venture Management LLC Makes New $27.58 Billion Investment in Pharvaris N.V. $PHVS
5AM Venture Management LLC bought a new stake in shares of Pharvaris N.V. (NASDAQ: PHVS) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 797,600 shares of the company's stock, valued at approximately $27,581,008,000. Pharvaris makes up approximately 9.6% of 5AM Venture Management
